Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas E Witzig

Showing results (61-70 of 387) with videos related to

Pageof 39
Sort By:
Clinical Lymphoma, Myeloma & Leukemia|April 11, 2022
Real World Long-term Follow-up Experience with Yttrium-90 ibritumomab tiuxetan in Previously Untreated Patients with Low-Grade Follicular Lymphoma and Marginal Zone LymphomaMuhamad Alhaj Moustafa, Jennifer Peterson, Bradford S Hoppe, et al.
JCO Oncology Practice|May 7, 2024
Should All Patients With Stage IE Gastric Mucosa-Associated Lymphoid Tissue Lymphoma Receive Antibiotic Eradication Therapy for <i>Helicobacter pylori</i>?Chonlada Laoruangroj, Thomas M Habermann, Yucai Wang, et al.
Blood|May 8, 2004
Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progressionShaji Kumar, Thomas E Witzig, Michael Timm, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 11, 2008
Rituximab therapy for refractory biliary strictures in immunoglobulin G4-associated cholangitisMark Topazian, Thomas E Witzig, Thomas C Smyrk, et al.
Experimental Hematology|May 27, 2006
Oncolytic measles virus targets high CD46 expression on multiple myeloma cellsHooi Tin Ong, Michael M Timm, Philip R Greipp, et al.
Blood|February 11, 2012
Elevated serum IL-10 levels in diffuse large B-cell lymphoma: a mechanism of aberrant JAK2 activationMamta Gupta, Jing Jing Han, Mary Stenson, et al.
American Journal of Hematology|January 3, 2014
Elevated serum monoclonal and polyclonal free light chains and interferon inducible protein-10 predicts inferior prognosis in untreated diffuse large B-cell lymphomaThomas E Witzig, Matthew J Maurer, Mary J Stenson, et al.
Blood|June 16, 2011
Cytotoxicity of farnesyltransferase inhibitors in lymphoid cells mediated by MAPK pathway inhibition and Bim up-regulationHusheng Ding, Jennifer Hackbarth, Paula A Schneider, et al.
Future Oncology (London, England)|April 19, 2016
ROBUST: Lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphomaGrzegorz S Nowakowski, Annalisa Chiappella, Thomas E Witzig, et al.
Haematologica|August 24, 2014
Anti-CD22 90Y-epratuzumab tetraxetan combined with anti-CD20 veltuzumab: a phase I study in patients with relapsed/refractory, aggressive non-Hodgkin lymphomaThomas E Witzig, Michael B Tomblyn, Jamal G Misleh, et al.
Pageof 39

Showing results (61-70 of 387) with videos related to

Sort By:
Pageof 39
Clinical Lymphoma, Myeloma & Leukemia|April 11, 2022
Real World Long-term Follow-up Experience with Yttrium-90 ibritumomab tiuxetan in Previously Untreated Patients with Low-Grade Follicular Lymphoma and Marginal Zone LymphomaMuhamad Alhaj Moustafa, Jennifer Peterson, Bradford S Hoppe, et al.
JCO Oncology Practice|May 7, 2024
Should All Patients With Stage IE Gastric Mucosa-Associated Lymphoid Tissue Lymphoma Receive Antibiotic Eradication Therapy for <i>Helicobacter pylori</i>?Chonlada Laoruangroj, Thomas M Habermann, Yucai Wang, et al.
Blood|May 8, 2004
Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progressionShaji Kumar, Thomas E Witzig, Michael Timm, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 11, 2008
Rituximab therapy for refractory biliary strictures in immunoglobulin G4-associated cholangitisMark Topazian, Thomas E Witzig, Thomas C Smyrk, et al.
Experimental Hematology|May 27, 2006
Oncolytic measles virus targets high CD46 expression on multiple myeloma cellsHooi Tin Ong, Michael M Timm, Philip R Greipp, et al.
Blood|February 11, 2012
Elevated serum IL-10 levels in diffuse large B-cell lymphoma: a mechanism of aberrant JAK2 activationMamta Gupta, Jing Jing Han, Mary Stenson, et al.
American Journal of Hematology|January 3, 2014
Elevated serum monoclonal and polyclonal free light chains and interferon inducible protein-10 predicts inferior prognosis in untreated diffuse large B-cell lymphomaThomas E Witzig, Matthew J Maurer, Mary J Stenson, et al.
Blood|June 16, 2011
Cytotoxicity of farnesyltransferase inhibitors in lymphoid cells mediated by MAPK pathway inhibition and Bim up-regulationHusheng Ding, Jennifer Hackbarth, Paula A Schneider, et al.
Future Oncology (London, England)|April 19, 2016
ROBUST: Lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphomaGrzegorz S Nowakowski, Annalisa Chiappella, Thomas E Witzig, et al.
Haematologica|August 24, 2014
Anti-CD22 90Y-epratuzumab tetraxetan combined with anti-CD20 veltuzumab: a phase I study in patients with relapsed/refractory, aggressive non-Hodgkin lymphomaThomas E Witzig, Michael B Tomblyn, Jamal G Misleh, et al.
Pageof 39